Deep Intelligent Pharma (DIP) secures US$60M in new funding to advance its transition into pharmaceutical infrastructure and promote the democratization of AI technology

Deep Intelligent Pharma (DIP), a globally leading AI-powered biotech unicorn, announced today the completion of a new financing round totaling US$60 million. Investors in this round include Trustar Capital, Jinyi Capital, and Kaitai Capital, with existing shareholders CDH Investments and Xinding Capital continuing to participate. Index Capital served as the exclusive financial advisor for this transaction. The proceeds will be primarily allocated to a generational upgrade of DIP's core technology system, aiming to accelerate DIP's strategic positioning as foundational infrastructure for the pharmaceutical industry.

DIP has successfully established the industry's first brain-science-based autonomous multi-agent ecosystem, known as the Synaptic Agent Ecosystem. This marks a shift from tool-oriented AI to an adaptive, decentralized, and self-evolving AI brain. DIP is continuously nurturing an autonomous agent neural network that operates like a biological brain, with its execution layer continuously accumulating practical experience to feed back and enrich its decision-making layer. Supported by a world model, the AI no longer computes blindly but truly "sees" and understands the world. As each node forms tens of thousands of synaptic-level connections, this collective intelligence has evolved autonomously over time, building an increasingly formidable technological barrier.

This financing round represents further validation from the capital market for DIP's technological vision. What DIP is building goes beyond tools that assist humans; it is cultivating a team of autonomous digital scientists endowed with domain-specific "consciousness." Through the decentralized collaboration and self-improvement of multiple agents, DIP is committed to transforming drug discovery and development from a labor-intensive industry into an autonomous, intelligence-driven decision-making ecosystem—making AI the true foundational infrastructure of pharmaceutical R&D.